Updates are available Correction dated 2024-04-16
Click to view Correction: https://doi.org/10.1038/s41467-024-47675-w
-
Authors
Hayes, Tikvah K.
Aquilanti, Elisa
Persky, Nicole S.
Yang, Xiaoping http://orcid.org/0000-0002-6811-4915
Kim, Erica E.
Brenan, Lisa
Goodale, Amy B.
Alan, Douglas
Sharpe, Ted
Shue, Robert E.
Westlake, Lindsay
Golomb, Lior
Silverman, Brianna R.
Morris, Myshal D.
Fisher, Ty Running
Beyene, Eden
Li, Yvonne Y. http://orcid.org/0000-0002-1741-1995
Cherniack, Andrew D. http://orcid.org/0000-0003-0470-0111
Piccioni, Federica http://orcid.org/0000-0003-1210-3210
Hicks, J. Kevin
Chi, Andrew S.
Cahill, Daniel P.
Dietrich, Jorg
Batchelor, Tracy T.
Root, David E. http://orcid.org/0000-0001-5122-861X
Johannessen, Cory M. http://orcid.org/0000-0002-2618-1036
Meyerson, Matthew http://orcid.org/0000-0002-9133-8108
-
Funding
Funding for this research was provided by:
National Institute of Cancer
- License Information
-
More Information
Article History
Received: 21 September 2023
Accepted: 30 January 2024
First Online: 28 March 2024
Change Date: 16 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-024-47675-w
Competing interests
: M.M. receives research support from Bayer Pharmaceuticals and Janssen. M.M. is a consultant for and equity holder in DelveBio, Interline and Isabl, and holds patents licensed to Bayer and LabCorp. C.M.J. is a full-time employee of and equity holder in Novartis. D.P.C. consults for the Massachusetts Institute of Technology, Advise Connect Inspire, German Accelerator, Lilly, GlaxoSmithKline, Incephalo, Boston Pharmaceuticals, Servier, Boston Scientific and Pyramid Biosciences (equity interest) for advisory input. He has also received financial compensation and travel reimbursement from Merck for invited lectures, and from the US NIH and DOD for clinical trial and grant review. F.P. is a full-time employee of Merck Research Laboratories. A.D.C. receives research support from Bayer Pharmaceuticals. D.E.R. receives research funding from members of the Functional Genomics Consortium (Abbvie, Bristol-Myers Squibb, Jannsen, Merck, Vir), and is a director of Addgene, Inc. A.S.C. is a full-time employee of and equity holder in Alterome Therapeutics. J.D. is a consultant for Novartis, Amgen, Janssen and Ono Therapeutics. N.S.P. is a full-time employee of Aera Therapeutics. The remaining authors declare no competing interests. J.K.H. serves as a consultant for Jackson Laboratory for Genomic Medicine.
